

A Carelon Company

OCREVUS (OCRELIZUMAB) ORDER SET

P: 877.365.5566 | **F:** 855.889.2946

PATIENT INFORMATION:	Fax completed form, insurance information, and clinical documentation to 855.889.2946	
Patient Name:	DOB: Phone:	
Patient Status: ☐ New to Therapy [Continuing Therapy Next Treatment Date:	
MEDICAL INFORMATION		
Diagnosis (ICD-10):		
☐ Relapsing-remitting MS (G35.A)	☐ Secondary progressive MS, unspecified (G35.C0)	
\square Primary progressive MS, unspecified (6	S35.B0) Secondary progressive MS, active (G35.C1)	
☐ Primary progressive MS, active (G35.B1) Secondary progressive MS, non-active (G35.C2)	
☐ Primary progressive MS, non-active (G	35.B2) ☐ MS, unspecified (G35.D)	
Patient Weight: lbs. (required) Allergies:		
THERAPY ORDER		
Ocrevus (ocrelizumab) IV:		
☐ Initial start: 300mg IV at 0 and 2 weeks, then 600mg IV every 6 months x 1 year		
☐ 600mg IV every 6 months x 1 year		
Pre-medication Orders: Solu-Medrol 100mg IV and diphenhydramine 25mg PO 30 minutes before infusion		
Substitute diphenhydramin	e with:	
☐ Loratac	line 10mg PO 🔲 Cetirizine 10mg PO 🔲 Cetirizine 10mg IV	
Ocrevus Zunovo (ocrelizumab/hy	aluronidase):	
920mg/23,000units subcutaneously every 6 months x 1 year		
Pre-medication Orders: dexamethasone 20mg PO & cetirizine 10mg PO 30 minutes before injection		
Other orders:		
	Lab Frequency:	
Required labs to be drawn by: 🔲 Pa		
 15-30kg (33-66lbs): EpiPen Jr. 0.1 Diphenhydramine: Administer 25-50mg NS 0.9% 1000mL IV bolus PRN per pro Refer to physician order or institutional 	tocol (adult) protocol for pediatric dosing PRN and Heparin 10U/mL or 100U/mL per protocol as indicated PRN	
PROVIDER INFORMATION		
Provider Name: Phone:	ing Paragon Healthcare, Inc. and its employees to serve as your prior authorization and specialty pharmacy designated panies, and to select the preferred site of care for the patient. Signature: Fax: Contact Person: f care (if checked, please list site of care):	
PREFERRED LOCATION		
City: State:	View our locations here:	

PARAGONHEALTHCARE.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.





COMPREHENSIVE SUPPORT FOR OCREVUS (OCRELIZUMAB) THERAPY

PATIENT INFORMATION:		
Patient Name:	DOB:	
REQUIRED DOCUMENTATION FOR REFERRAL PROCE	SSING & INSURANCE APPROVAL	
\square Include <u>signed</u> and <u>completed</u> order (MD/prescriber	to complete page 1)	
☐ Include patient demographic information and insurar	nce information	
☐ Include patient's medication list		
☐ Supporting clinical notes to include any past tried an benefits, or contraindications to therapy	d/or failed therapies, intolerance,	
☐ Expanded Disability Status Scale (EDSS) score: _		
$\hfill\square$ Include labs and/or test results to support diagnosis		
☐ MRI		
☐ If applicable - Last known biological therapy: If patient is switching biologic therout period of weeks prior to starting oc	apies, please perform a wash-	
Other medical necessity:		
REQUIRED PRE-SCREENING		
□ Hepatitis B screening test completed. This includes B core antibody total (not IgM) - attach results □ Positive □ Negative *If Hepatitis B results are positive - please provide documentation of treatment or m □ Liver function tests including bilirubin		

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance